DUBLIN, Jan 25, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Myasthenia Gravis Drugs Market 2017-2021" report to their offering.
The global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.
Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, myasthenia gravis is the common disorder of neuromuscular transmission. The presence of large patient pool with myasthenia gravis is expected to fuel the market growth. The data estimates suggest that out of the existing patient pool in the US, approximately 15%-20% of people will experience a myasthenic crisis (a complication of myasthenia gravis resulting in severe muscle weakness, leading to respiratory failure). Three-fourths of these cases experience their first crisis within two years of diagnosis. Further, the disease is increasingly affecting the pediatric population, which will, in turn, increase the overall patient pool, thereby fueling the market growth.
Further, the report states that the growing preference for substitutes such as thymectomy could hinder the growth prospects in the market. Thymectomy is mandatory in individuals with thymoma and is recommended as an alternative for non-thymomatous individuals with generalized myasthenia gravis. Particularly in individuals with acetylcholine antibodies and younger than 60 years, to enhance the likelihood of remission or improvement. Thymectomy therapy offers long-term benefit to an individual by reducing or stopping the existing chronic medical therapies. In addition, there has been growing support from healthcare organizations to opt for thymectomy.
- Flamel Technologies
- F. Hoffmann-La Roche
- Valeant Pharmaceuticals
Other prominent vendors
- Alexion Pharmaceuticals
- Catalyst Pharmaceuticals
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Pipeline analysis
Part 06: Market landscape
Part 07: Market segmentation by therapy area
Part 08: Geographical segmentation
Part 09: Market drivers
Part 10: Impact of drivers
Part 11: Market challenges
Part 12: Impact of drivers and challenges
Part 13: Market trends
Part 14: Vendor landscape
Part 15: Key vendor analysis
Part 16: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/v3c3hq/global_myasthenia
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-myasthenia-gravis-drugs-market-to-grow-at-a-cagr-of-1316-by-2021-key-vendors-are-flamel-technologies-f-hoffmann-la-roche-grifols-pfizer-shire--valeant-pharmaceuticals-300396457.html
SOURCE Research and Markets